Sanctions Sought In Discovery Spat V. Mutual Pharma

Law360, New York (September 8, 2009, 4:35 PM EDT) -- The plaintiffs in a product liability case against Mutual Pharmaceuticals Co. Inc. over the generic drug sulindac, marketed by Merck & Co. under the brand name Clinoril,

have asked a federal judge to sanction Mutual, alleging it made false statements regarding the availability of years' worth of federally required safety reports regarding the drug.

Attorneys for Karen L. Bartlett and Gregory S. Bartlett filed the motion for sanctions Tuesday in the U.S. District Court for the District of New Hampshire.

In general, the Bartletts allege that...
To view the full article, register now.